We are live on
!
Find out more
BCV
Banque Cantonale Vaudoise Portfolio holdings
AUM
$722M
1-Year Est. Return
30.45%
This Fund
S&P 500
This Quarter
Est. Return
+16.26%
1 Year Est. Return
+30.45%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$722M
AUM Growth
-$1.94B
(-73%)
Cap. Flow
-$438M
Cap. Flow
% of AUM
-60.67%
Top 10 Holdings %
Top 10 Hldgs %
58.22%
Holding
956
New
82
Increased
260
Reduced
372
Closed
140
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$21.9M |
| 2 |
AstraZeneca
AZN
|
+$11.4M |
| 3 |
AMRZ
Amrize Ltd
AMRZ
|
+$10.6M |
| 4 |
Johnson & Johnson
JNJ
|
+$8.1M |
| 5 |
Walmart Inc
WMT
|
+$5.76M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$85.9M |
| 2 |
Amazon
AMZN
|
+$49.2M |
| 3 |
Applied Materials
AMAT
|
+$15.5M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$14.3M |
| 5 |
Advanced Micro Devices
AMD
|
+$13.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.44% |
| 2 | Healthcare | 20.15% |
| 3 | Communication Services | 15.97% |
| 4 | Industrials | 10.45% |
| 5 | Materials | 10.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
551
Hilton Worldwide
HLT
$70B
| $398 | ﹤0.01% |
1,204
-2,622
| -69% | -$862K |
|
552
Sana Biotechnology
SANA
$1.15B
| $398 | ﹤0.01% |
114,000
+23,302
| +26% | +$75.1K |
|
553
John Wiley & Sons Class A
WLY
$2.44B
| $398 | ﹤0.01% |
+8,207
| New | +$345K |
|
554
Fidelity National Information Services
FIS
$21.6B
| $393 | ﹤0.01% |
10,116
-1,127
| -10% | -$48.8K |
|
555
iShares US Medical Devices ETF
IHI
$3.43B
| $393 | ﹤0.01% |
7,957
-215
| -3% | -$10.9K |
|
556
Southern Company
SO
$101B
| $392 | ﹤0.01% |
4,097
-14,173
| -78% | -$1.33M |
|
557
Global Payments
GPN
$24.5B
| $388 | ﹤0.01% |
5,348
+486
| +10% | +$33.5K |
|
558
Match Group
MTCH
$9.61B
| $388 | ﹤0.01% |
+10,187
| New | +$361K |
|
559
GlobalFoundries
GFS
$24.8B
| $387 | ﹤0.01% |
4,691
-1,743
| -27% | -$122K |
|
560
Kenvue
KVUE
$36B
| $387 | ﹤0.01% |
20,230
-41,476
| -67% | -$731K |
|
561
PTC
PTC
$15.3B
| $380 | ﹤0.01% |
3,349
-502
| -13% | -$67.8K |
|
562
Entergy
ETR
$51.3B
| $377 | ﹤0.01% |
3,281
-4,684
| -59% | -$528K |
|
563
iShares iBonds Dec 2030 Term Corporate ETF
IBDV
$3.29B
| $376 | ﹤0.01% |
17,251
+145
| +0.8% | +$3.16K |
|
564
Quest Diagnostics
DGX
$26.2B
| $372 | ﹤0.01% |
1,756
-6
| -0.3% | -$1.18K |
|
565
Eversource Energy
ES
$26.8B
| $372 | ﹤0.01% |
5,151
+1,295
| +34% | +$89.7K |
|
566
Vanguard S&P 500 ETF
VOO
$1.03T
| $372 | ﹤0.01% |
542
+199
| +58% | +$133K |
|
567
Summit Therapeutics
SMMT
$14B
| $367 | ﹤0.01% |
25,195
+1,279
| +5% | +$22.7K |
|
568
EQT Corp
EQT
$34.5B
| $365 | ﹤0.01% |
6,856
+1,574
| +30% | +$88.3K |
|
569
iShares Biotechnology ETF
IBB
$10.6B
| $362 | ﹤0.01% |
1,905
| – | – |
|
570
iShares JPMorgan USD Emerging Markets Bond ETF
EMB
$15B
| $358 | ﹤0.01% |
3,710
| – | – |
|
571
iShares US Financials ETF
IYF
$4.37B
| $357 | ﹤0.01% |
2,803
+805
| +40% | +$99.9K |
|
572
iShares Core MSCI Europe ETF
IEUR
$9.37B
| $346 | ﹤0.01% |
4,600
| – | – |
|
573
Moderna
MRNA
$58.1B
| $346 | ﹤0.01% |
4,944
+3,821
| +340% | +$198K |
|
574
iShares iBonds Dec 2031 Term Corporate ETF
IBDW
$2.54B
| $343 | ﹤0.01% |
16,438
+274
| +2% | +$5.72K |
|
575
Tower Semiconductor
TSEM
$25.1B
| $337 | ﹤0.01% |
1,293
-3,114
| -71% | -$746K |
|
Similar funds
AO
HS
GFM
SFG
ACM
SCM
SP
SFS
Banque Cantonale Vaudoise's Q2 2026 Portfolio in Review
As of Q2 2026, Banque Cantonale Vaudoise held 956 positions worth $722M, down 73% from $2.66B the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Banque Cantonale Vaudoise withdrew a net $438M in Q2 2026, closing 140 positions and reducing 372 holdings. Its most notable exit was Apple, an estimated $85.9M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 28% a quarter earlier, followed by Healthcare and Communication Services.
Against the trend, Banque Cantonale Vaudoise opened a new position in AstraZeneca worth $11.3M.
- Banque Cantonale Vaudoise's largest Q2 2026 buy was AstraZeneca: 60,462 shares worth $11.3M.
- Banque Cantonale Vaudoise added most to Microsoft in Q2 2026, an estimated $21.9M increase.
- Banque Cantonale Vaudoise's biggest Q2 2026 reduction was Alphabet (Google) Class A, cutting an estimated $14.3M.
- Banque Cantonale Vaudoise fully exited Apple in Q2 2026, selling an estimated $85.9M.
- Banque Cantonale Vaudoise's ten largest holdings make up 58% of its $722M portfolio in Q2 2026.
- Banque Cantonale Vaudoise opened 82 new positions and closed 140 in Q2 2026.
- Banque Cantonale Vaudoise's portfolio value fell 73% quarter-over-quarter to $722M.
Based on Banque Cantonale Vaudoise's 13F filing for Q2 2026, filed 31 Jul 2026.